McKesson Corporation
McKesson Reports Preliminary Q4 and FY 2024 Results
Summary
McKesson Corporation reported preliminary results for the quarter and fiscal year ended March 31, 2024. For the quarter, consolidated revenues increased by 11% to $76.4 billion, and earnings per diluted share from continuing operations increased by $0.31 to $6.02. However, Adjusted Earnings per Diluted Share decreased by 14%. For the full year, consolidated revenues increased by 12% to $309.0 billion, and earnings per diluted share from continuing operations decreased by $2.66 to $22.39. Adjusted Earnings per Diluted Share increased by 6% to $27.44. These results are accompanied by an earnings release and cover page interactive data file.
Get alerts for MCK
Be first to know when McKesson Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About McKesson Corporation
McKesson Corporation is a leading healthcare services and information technology company. It plays a crucial role in the distribution of pharmaceuticals and medical products. The primary function of McKesson is to ensure the efficient delivery of healthcare products to pharmacies, hospitals, and other medical facilities, ensuring that millions of patients have access to the medications they need. It also provides specialized software and automated solutions that enhance operational efficiency in healthcare sectors. McKesson significantly impacts the pharmaceutical and healthcare industries by offering solutions that streamline supply chains and improve patient care. Its services encompass wholesale drug distribution, healthcare IT systems, and pharmacy management. With operations that extend globally, McKesson is integral to maintaining the integrity and reliability of healthcare supply networks. By handling a substantial portion of the pharmaceutical distribution in North America, McKesson Corporation has a vital market presence, emphasizing its importance in shaping healthcare logistics and innovation. Its efforts contribute to advancing healthcare delivery and responding to the evolving demands of the medical industry.
Official SEC Documents
Advertisement